The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Site-specific antibody drug conjugates for cancer therapy
Open accessAbstract
Antibody therapeutics have revolutionized the treatment of cancer over the past two decades. Antibodies that specifically bind tumor surface antigens can be effective therapeutics; however, many unmodified antibodies lack therapeutic activity. These antibodies can instead be applied successfully as guided missiles to deliver potent cytotoxic drugs in the form of antibody drug conjugates (ADCs). The success of ADCs is dependent on four factors--target antigen, antibody, linker, and payload. The field has made great progress in these areas, marked by the recent approval by the US Food and Drug Administration of two ADCs, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla). However, the therapeutic window for many ADCs that are currently in pre-clinical or clinical development remains narrow and further improvements may be required to enhance the therapeutic potential of these ADCs. Production of ADCs is an area where improvement is needed because current methods yield heterogeneous mixtures that may include 0-8 drug species per antibody molecule. Site-specific conjugation has been recently shown to eliminate heterogeneity, improve conjugate stability, and increase the therapeutic window. Here, we review and describe various site-specific conjugation strategies that are currently used for the production of ADCs, including use of engineered cysteine residues, unnatural amino acids, and enzymatic conjugation through glycotransferases and transglutaminases. In addition, we also summarize differences among these methods and highlight critical considerations when building next-generation ADC therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characterization of Mammalian Selenoproteomes
Kryukov, G. V., Castellano, S., Novoselov, S. V., Lobanov, A. V., Zehtab, O., Guigó, R., & Gladyshev, V. N. (2003) · Science · doi:10.1126/science.1083516 · Cited by 2,351
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Self-citationEffects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Self-citationKiick, K. L., Saxon, E., Tirrell, D. A., & Bertozzi, C. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012583299 · Cited by 910
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli
Young, T. S., Ahmad, I., Yin, J. A., & Schultz, P. G. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.10.030 · Cited by 637
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Properties and applications of microbial transglutaminase
Yokoyama, K., Nio, N., & Kikuchi, Y. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1539-5 · Cited by 605
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211023109 · Cited by 596
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Strop, P., Liu, S.-H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T.-T., Ho, W.-H., Farias, S., Casas, M. G., Abdiche, Y., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.01.010 · Cited by 505
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Introducing genetically encoded aldehydes into proteins
Carrico, I. S., Carlson, B. L., & Bertozzi, C. R. (2007) · Nature Chemical Biology · doi:10.1038/nchembio878 · Cited by 438
Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus
Kupchan, S. M., Komoda, Y., Court, W. A., Thomas, G. J., Smith, R. M., Karim, A., Gilmore, C. J., Haltiwanger, R. C., & Bryan, R. F. (1972) · Journal of the American Chemical Society · doi:10.1021/ja00759a054 · Cited by 434
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Genetic incorporation of unnatural amino acids into proteins in mammalian cells
Liu, W., Brock, A., Chen, S., Chen, S., & Schultz, P. G. (2007) · Nature Methods · doi:10.1038/nmeth1016 · Cited by 373
Addition of the keto functional group to the genetic code of Escherichia coli
Wang, L., Zhang, Z., Brock, A., & Schultz, P. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0234824100 · Cited by 356
Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Jeger, S., Zimmermann, K., Blanc, A., Grünberg, J., Honer, M., Hunziker, P., Struthers, H., & Schibli, R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201004243 · Cited by 344
Antimitotic Activity of the Potent Tumor Inhibitor Maytansine
Remillard, S., Rebhun, L. I., Howie, G. A., & Kupchan, S. M. (1975) · Science · doi:10.1126/science.1241159 · Cited by 337
Ritchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0987 · Cited by 292
Self-citationRandomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Self-citationSite-specific chemical protein conjugation using genetically encoded aldehyde tags
Rabuka, D., Rush, J. S., deHart, G. W., Wu, P., & Bertozzi, C. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.045 · Cited by 246
Substrate-induced conformational changes in glycosyltransferases
Qasba, P. K., Ramakrishnan, B., & Boeggeman, E. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.005 · Cited by 246
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
Schwartz, R. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048021 · Cited by 221
Boger, D. L., & Johnson, D. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3642 · Cited by 217
Drug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Boswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N. R., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., Saad, O., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200212a · Cited by 207
Moldenhauer, G., Salnikov, A. V., Lüttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs140 · Cited by 199
Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 196
Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., Slovak, M. L., Tallman, M. S., Willman, C. L., Erba, H., et al. (2009) · Blood · doi:10.1182/blood.v114.22.790.790 · Cited by 184
shRNA and siRNA delivery to the brain
Pardridge, W. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.008 · Cited by 176
The development of pyrrolobenzodiazepines as antitumour agents
Hartley, J. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573477 · Cited by 175
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 170
Thorson, J., Sievers, E., Ahlert, J., Shepard, E., Whitwam, R., Onwueme, K., & Ruppen, M. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003398564 · Cited by 166
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., & Lowman, H. B. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.12.011 · Cited by 165
Self-citationAntibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Steiner, M., & Neri, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0483 · Cited by 157
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 156
Yin, G., Garces, E. D., Yang, J., Zhang, J., Tran, C., Steiner, A. R., Roos, C. M., Bajad, S. U., Hudak, S. A., Penta, K., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19202 · Cited by 151
Antibody-Drug Conjugate Targets
Teicher, B. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192365 · Cited by 142
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M. E., Law, C., Senter, P. D., & Benjamin, D. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155549 · Cited by 136
Boeggeman, E. E., Ramakrishnan, B., Pasek, M., Manzoni, M., Puri, A., Loomis, K. H., Waybright, T. J., & Qasba, P. K. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900103p · Cited by 114
Molecularly Defined Antibody Conjugation through a Selenocysteine Interface
Höfer, T., Skeffington, L. R., Chapman, C. M., & Rader, C. M. (2009) · Biochemistry · doi:10.1021/bi901744t · Cited by 104
Wootton, S. K., & Yoo, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4546-4557.2003 · Cited by 102
Site specific protein labeling by enzymatic posttranslational modification
Sünbül, M., & Yin, J. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b908687k · Cited by 90
Polson, A. G., Williams, M. B., Gray, A. M., Fuji, R. N., Poon, K. A., McBride, J., Raab, H. E., Januario, T., Go, M. A. T., Lau, J., et al. (2010) · Leukemia · doi:10.1038/leu.2010.141 · Cited by 88
Self-citationGerber, H., Sutherland, M. K., Stone, I. J., Morris-Tilden, C. A., Miyamoto, J. B., McCormick, R. S., Alley, S. C., Okeley, N. M., Hayes, B., Hernandez‐Ilizaliturri, F. J., et al. (2009) · Blood · doi:10.1182/blood-2008-09-179143 · Cited by 85
Elias, D. J., Hirschowitz, L., Kline, L. E., Kroener, J. F., Dillman, R. O., Walker, L. E., Robb, J. A., & Timms, R. M. (1990) · PubMed · Cited by 85
PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine
Dere, R. C., Yi, J., Lei, C., et al. (2013) · Bioanalysis · doi:10.4155/bio.13.72 · Cited by 75
Woo, H. J., Lotz, M. M., Jung, J. U., et al. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55075-4 · Cited by 69
Size matters: a view of selenocysteine incorporation from the ribosome
Caban, K., & Copeland, P. R. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5402-y · Cited by 53
Gemtuzumab Ozogamicin: One Size Does Not Fit All—The Case for Personalized Therapy
Ravandi, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2693 · Cited by 31
Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case
Ronca, R., Sozzani, S., Presta, M., & Alessi, P. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.06.005 · Cited by 30
Tan, M., Vernes, J.-M., Chan, J. C. Y., Cuellar, T. L., Asundi, A., Nelson, C., Yip, V., Shen, B., VANDLEN, R. L., Siebel, C. W., et al. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.08.018 · Cited by 19
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A. (2015) · Molecules · doi:10.3390/molecules200916852 · Cited by 716
Agarwal, P., & Bertozzi, C. R. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004982 · Cited by 605
Metadata
- Authors
- Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2013-11
- Volume
- 6
- Issue
- 1
- Pages
- 34-45
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2150244588
- Cited by
- 676
- References
- 65
- FWCI
- 46.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.